Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

505
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
505
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

363
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
363
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

575
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
575
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

570
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
570

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Secondary Mitral and Tricuspid Regurgitation in Early HFrEF: The Impact of Contemporary Medical Therapy.

European journal of heart failure·2026
Same author

An Alternative Path in Transthyretin Amyloid Cardiomyopathy.

European journal of heart failure·2026
Same author

Neutrophil-to-lymphocyte ratio and C-reactive protein in patients admitted with Acute Dyspnoea suspected of acute heart failure.

International journal of cardiology·2026
Same author

Future for cardiogenic shock research.

Current opinion in critical care·2024
Same author

Biomarker patterns in patients with cardiogenic shock versus septic shock.

International journal of cardiology. Heart & vasculature·2024
Same author

Acute kidney injury after out-of-hospital cardiac arrest.

Critical care (London, England)·2024
Same journal

Public Health Response to Clade Ib Mpox with Multiple Exposures in Congregate Living Settings - New Hampshire, February 2025.

NEJM evidence·2026
Same journal

Berberine-Ursodeoxycholate - Bringing Traditional Chinese Medicine to Our World.

NEJM evidence·2026
Same journal

Outbreak of Legionnaires' Disease Associated with Cooling Tower Systems in Central Harlem.

NEJM evidence·2026
Same journal

Immunotherapy for Fertility in Autoimmune Premature Ovarian Insufficiency.

NEJM evidence·2026
Same journal

A Randomized Trial of Interval Likelihood Ratios for Clinical Decision-Making.

NEJM evidence·2026
Same journal

Evidence for Evidence-Based Medicine - A Call for Some Theory and a New Problem.

NEJM evidence·2026
See all related articles

Related Experiment Video

Updated: Jun 25, 2025

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
07:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 15, 2010

43.7K

Vasodilators for Acute Heart Failure - A Systematic Review with Meta-Analysis.

Jasmin D Lukoschewitz1, Kristina C Miger2, Anne Sophie O Olesen2

  • 1Department of Cardiology, Hvidovre Hospital, Copenhagen University Hospital, Copenhagen.

NEJM Evidence
|May 28, 2024
PubMed
Summary
This summary is machine-generated.

Vasodilators did not reduce all-cause mortality in acute heart failure patients. However, they were associated with a lower risk of tracheal intubation in this systematic review.

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.4K
Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

9.3K

Related Experiment Videos

Last Updated: Jun 25, 2025

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
07:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 15, 2010

43.7K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.4K
Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

9.3K

Area of Science:

  • Cardiology
  • Critical Care Medicine
  • Pharmacology

Background:

  • Acute heart failure (AHF) presents a significant public health challenge.
  • Effective AHF management strategies are crucial for improving patient outcomes.
  • This study systematically reviewed evidence on vasodilator use in AHF.

Purpose of the Study:

  • To evaluate the efficacy and safety of vasodilators in patients with acute heart failure.
  • To synthesize findings from randomized clinical trials (RCTs) through meta-analysis.

Main Methods:

  • A comprehensive search of multiple databases (Medline, Embase, etc.) was performed.
  • Inclusion criteria focused on RCTs comparing vasodilators with standard care, placebo, or cointerventions.
  • Primary outcome was all-cause mortality; secondary outcomes included serious adverse events (SAEs), tracheal intubation, and hospital stay. Risk of bias was assessed.

Main Results:

  • The meta-analysis included 46 RCTs with 28,374 patients.
  • Vasodilators did not significantly reduce all-cause mortality (RR, 0.95; 95% CI, 0.87-1.04).
  • No significant differences were observed in SAEs or length of hospital stay. Vasodilator use was linked to reduced tracheal intubation (RR, 0.54; 95% CI, 0.30-0.99).

Conclusions:

  • Vasodilators do not appear to reduce all-cause mortality in patients with acute heart failure.
  • The findings suggest a potential benefit in reducing tracheal intubation rates.
  • Further research may clarify the role of vasodilators in AHF management.